日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

晚期胆道癌患者接受吉西他滨、顺铂和白蛋白紫杉醇治疗后疗效的分子决定因素

Kim, Daeseong; Sim, Nam Suk; Woo, Seonjeong; Kim, Min Hwan; Lee, Choong-Kun; Hong, Seung Soo; Kim, Sung Hyun; Hwang, Ho Kyoung; Kang, Chang Moo; Lee, Woo Jung; Jo, Jung Hyun; Chung, Taek; Hwang, Sohyun; Kang, Beodeul; Kim, Jung Sun; Kwon, Chang-Il; Kim, Sangwoo; Chon, Hong Jae; Kim, Chang Gon; Park, Young Nyun; Choi, Hye Jin

Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features

整合多组学分析表明,浸润性肝细胞癌是一种具有独特分子特征的免疫治疗耐药亚型。

Lee, Won Suk; Woo, Seonjeong; Lee, Sung Hwan; Jo, Gae Hoon; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jung, Sanghoon; Kim, Gwangil; Kang, Haeyoun; Kang, Beodeul; Kim, Jung Sun; Lim, Ho Yeong; Kang, Incheon; Yang, Hannah; Kong, So Jung; Son, Dahyeon; Shin, Dong Jun; Kwon, Woo Young; Lee, Da-Yeon; Lee, Ju-Seog; Park, Junho; Kim, Youngsoo; Hwang, Sohyun; Kim, Chan; Chon, Hong Jae

Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab

血浆GPC3水平反映肿瘤GPC3表达,并可预测接受阿特珠单抗+贝伐珠单抗治疗的晚期肝细胞癌患者的临床疗效。

Shin, Dong Jun; Hwang, Sohyun; Kang, Beodeul; Lee, Won Suk; Kong, So Jung; Yang, Hannah; Kang, Haeyoun; Lee, Sung Hwan; Kim, Jung Sun; Heo, Jinhyung; Lim, Ho Yeong; Shi, Jingwen; Tong, Yongchun; Kim, Gwangil; Kim, Chan; Chon, Hong Jae

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

晚期肝细胞癌患者在接受阿特珠单抗联合贝伐珠单抗治疗后,再接受纳武利尤单抗联合伊匹木单抗治疗的疗效:一项国际多中心研究

Kim, Jung Sun; Wong, Jeffrey; Chen, San-Chi; Tai, David; Yang, Hannah; Kim, Youngun; Kang, Beodeul; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jang, Su Jin; Kudo, Masatoshi; Lim, Ho Yeong; Kim, Chan; Yau, Thomas; Chon, Hong Jae

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial

新辅助FOLFIRINOX方案治疗可切除胰腺癌的疗效(NeoFOL-R):一项国际多中心前瞻性随机对照试验的研究方案

Jung, Hye-Sol; Choi, Julian; Park, Se Jun; Han, Youngmin; Cho, Young Jae; Yoon, Jeesun; Oh, Do-Youn; Yoon, Yoo-Seok; Kim, Jin Won; Lim, Chang-Sup; Park, Jin Hyun; Choi, In Sil; Hong, Tae Ho; Kim, Hyung Sun; Jeung, Hei-Cheul; Ahn, Keun Soo; Kim, Jin Young; Yu, Young-Dong; Kim, Ju Won; Hwang, Ho Kyoung; Lee, Choong-Kun; Choi, Hye Jin; Jung, Yun Kyung; Park, Kwonoh; Yoon, Jai Hoon; Han, In Woong; Hong, Jung Yong; Seo, Hyung Il; Do Yang, Jae; Jeon, So-Yeon; Yang, Seok Jeong; Chon, Hong Jae; Kwon, Wooil; Park, Joon Seong; Shan, Yan-Shen; Lee, Myung Ah; Jang, Jin-Young

Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches

肝细胞癌免疫相关不良事件:器官特异性模式和处理方法

Choi, Sul Ki; Woo, Seonjeong; Chon, Hong Jae

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

阿特珠单抗联合化疗(加或不加贝伐珠单抗)治疗晚期胆道癌:来自随机II期IMbrave151试验的临床和生物标志物数据

Macarulla, Teresa; Ren, Zhenggang; Chon, Hong Jae; Park, Joon Oh; Kim, Jin Won; Pressiani, Tiziana; Li, Daneng; Zhukova, Lyudmila; Zhu, Andrew X; Chen, Ming-Huang; Hack, Stephen P; Wu, Stephanie; Liu, Bo; Guan, Xiangnan; Lu, Shan; Wang, Yulei; El-Khoueiry, Anthony B

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

初步验证基于机器学习的肿瘤免疫浸润评估方法作为阿特珠单抗联合贝伐珠单抗治疗肝细胞癌患者预后预测指标的有效性

Scheiner, Bernhard; Lombardi, Pasquale; D'Alessio, Antonio; Kim, Gwangil; Tafavvoghi, Masoud; Petrenko, Oleksandr; Goldin, Robert D; Fulgenzi, Claudia A M; Torkpour, Aria; Balcar, Lorenz; Mauri, Francesco A; Pomej, Katharina; Himmelsbach, Vera; Barsch, Maryam; Celsa, Ciro; Cabibbo, Giuseppe; Cheon, Jaekyung; Krall, Anja; Hucke, Florian; Di Tommaso, Luca; Bernasconi, Monica; Rimassa, Lorenza; Samson, Adel; Stefanini, Bernardo; Mozayani, Behrang; Trauner, Michael; Lackner, Carolin; Stauber, Rudolf; Vasuri, Francesco; Piscaglia, Fabio; Bengsch, Bertram; Finkelmeier, Fabian; Peck-Radosavljevic, Markus; Rasmussen Busund, Lill-Tove; Marafioti, Teresa; Rahbari, Mohammad; Heikenwalder, Mathias; Pinter, Matthias; Chon, Hong Jae; Rakaee, Mehrdad; Pinato, David J

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

一项多中心 II 期试验,评估瑞戈非尼二线治疗在接受阿特珠单抗联合贝伐珠单抗治疗后进展的不可切除肝细胞癌患者的疗效

Cheon, Jaekyung; Ryoo, Baek-Yeol; Chon, Hong Jae; Kim, Hyung-Don; Ryu, Min-Hee; Kim, Kyu-Pyo; Kang, Beodeul; Finn, Richard S; Chan, Stephen Lam; Yoo, Changhoon

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

阿特珠单抗联合贝伐珠单抗治疗晚期肝细胞癌患者循环肿瘤DNA的临床可行性

Hwang, Sohyun; Shin, Dong Jun; Kang, Beodeul; Kang, Haeyoun; Lee, Sung Hwan; Kim, Jung Sun; Joung, Je-Gun; Jain, Suyog; Olsen, Steven; Becker, Lars; Finn, Richard S; Llovet, Josep M; Kim, Gwangil; Kim, Chan; Chon, Hong Jae